


Our Innovation Network



About Roche and Genentech

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotechnology company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in *in vitro* diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Genentech, considered to be the founder of the biotechnology industry, became a wholly owned member of the Roche Group in March 2009. Genentech now serves as the headquarters for Roche's pharmaceutical operations in North America. Genentech Research and Early Development continues to embrace the spirit of a "startup" and operates as an independent R&D center within the Roche Group.

A Leader in Personalized Healthcare

PHARMACEUTICALS

4 FDA BREAKTHROUGH THERAPY DESIGNATIONS

granted for Roche medicines in 2015

25 MILLION PATIENTS

treated with one of our top 25 selling medicines

126 MILLION PATIENTS

receiving Roche medicines that are now off-patent

324 THOUSAND PATIENTS

participated in clinical trials

DIAGNOSTICS

15 BILLION TESTS

conducted in 2015 with Roche instruments worldwide

>7 MILLION INFANTS

have been HIV-tested through a Roche Diagnostics global access program since 2002

INDUSTRY LEADERSHIP

#1

in biotechnology, oncology, *in vitro* diagnostics & hospital market

7 YEARS RUNNING

Roche ranked as the most sustainable healthcare company by the Dow Jones Sustainability Indices

91,747 EMPLOYEES

100+ COUNTRIES

How to Invest

FOR U.S. INVESTORS INTERESTED IN INVESTING IN THE ROCHE GROUP:

Learn more about Roche's U.S. dollar-denominated American Depositary Receipt or ADR (ADR stock symbol: RHHBY) from the following link <http://www.roche.com/investors/contacts.htm>.

Roche ADRs can be bought or sold through any U.S. registered brokerage. They trade, clear and settle like any U.S. shares and are held in U.S. custody by J.P. Morgan, Roche's depository bank. The Roche Group also trades on the SIX Swiss Exchange (symbols: ROG.VX for the non-voting equity security and RO.S for the voting share).

Contact Information

Investor Relations North America
Roche Holdings, Inc.
Genentech, Inc.
1 DNA Way, South San Francisco, CA 94080
Email: rocheirna@gene.com
Website: www.gene.com/about-us/investors

Additional Information

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Information accessed herein may not under any circumstances be used for the purpose of, or in connection with, the quotation of any securities on an automated inter-dealer quotation system within the meaning of Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Overview of Our Financials

2015 ROCHE GROUP

48.1 CHF | 50.2 USD*
BILLION IN SALES
(PHARMACEUTICALS AND DIAGNOSTICS)
80% OF PHARMACEUTICAL SALES ARE
ATTRIBUTED TO BIOTECHNOLOGY PRODUCTS

17.5 CHF | 18.3 USD*
BILLION IN CORE OPERATING PROFIT

9.3 CHF | 9.7 USD*
BILLION IN R&D INVESTMENT


29 years
IN A ROW OF
INCREASED DIVIDENDS

OVERALL NET SALES FIGURES

SALES BY BUSINESS AREAS FOR PHARMACEUTICALS (INCLUDING BIOTECHNOLOGY) AND DIAGNOSTICS FOR THE PAST THREE YEARS


CHF

TOTAL
BILLIONS




USD*

TOTAL
BILLIONS




RESEARCH & DEVELOPMENT

TOTAL BILLIONS




CORE OPERATING PROFIT

TOTAL BILLIONS




CORE EARNINGS PER SHARE



OPERATING FREE CASH FLOW

TOTAL BILLIONS



* Exchange rate used CHF/USD: 0.96 (2015), 0.91 (2014), 0.93 (2013)

† USD per ADR where currently, eight ADRs represent one underlying non-voting equity security

SHARING OUR SUCCESS WITH INVESTORS


DIVIDEND HISTORY FOR THE LAST 29 YEARS AND CASH RETURNED TO SHAREHOLDERS

Roche's ADR (American Depositary Receipt) is listed in the U.S. on OTCQX International Premier under the symbol **RHHBY**. Traded in U.S. dollars, eight ADRs represent one underlying non-voting equity security **ROG.VX** (Genussschein, abbreviated NES).

For more information, visit http://www.roche.com/investors/financial_data/shares/us_investors.htm.


GROSS DIVIDEND FOR ROCHE - ROG.VX

29-YEAR DIVIDEND (CHF)



GROSS DIVIDEND FOR ROCHE ADR - RHHBY

23-YEAR DIVIDEND (USD)



5-YEAR DIVIDEND HISTORY

	DIVIDENDS PER SHARE	GROSS DIVIDEND
	ROG.VX CHF	RHHBY USD* per ADR
2015	8.10	1.02
2014	8.00	1.00
2013	7.80	1.11
2012	7.35	0.97
2011	6.80	0.92

† Exchange rate as determined by the depositary bank during the dividend payment and tax reclaim process

Our Pharmaceutical Successes

Eight of the Roche Group's top 10 selling pharmaceuticals are blockbusters that have sales of more than 1B CHF/USD per year. Of the eight blockbusters, seven are biotechnology products. The Roche Group also currently has one of the strongest pharmaceutical development pipelines in the industry, with biotechnology products accounting for a significant part of all projects. For more information, visit: http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm.

ROCHE PHARMACEUTICAL PRODUCTS


In 2015, global sales of the Roche Group's top five pharmaceutical products were:

TOTAL SALES IN BILLIONS



ROCHE PHARMACEUTICAL PIPELINE

In 2015, the Roche Group's pharmaceutical pipeline included:



Exchange rate used CHF/USD: 0.96 (2015)

Copyright © 22 April 2016 by Roche Investor Relations North America, South San Francisco.